strategic alternatives
Talis Biomedical Lays Off 90 Percent of Workforce, Will Explore Strategic Alternatives
The company's board of directors has appointed a special committee of independent directors to consider a range of strategic alternatives.
Shareholder Calls on Cue Health to Begin Strategic Review, Realign Costs
The shareholder, Tarsadia Investments, noted concerns about Cue's cost structure and future business plans.
Enzo Biochem Fiscal Q3 Revenues Fall 20 Percent; Firm Examining Strategic Alternatives
Enzo has engaged investment bank Jefferies to evaluate strategic alternatives for the company and its various divisions and assets.
OraSure Misses COVID-19 Antigen Test Sales Guidance; Announces CEO Departure, Strategic Review
OraSure expects to miss its full-year rapid COVID-19 antigen test sales estimate by $10 million, and will now undertake a strategic review.
Fluidigm Q3 Revenues Drop 29 Percent on Supply Chain Issues, Waning COVID-19 Testing
The company also lowered its full-year financial guidance and said its board of directors is undertaking a strategic review to maximize shareholder value.
Jun 10, 2019
Enzo Biochem Fiscal Q3 Revenues Decline 22 Percent
Apr 2, 2018
Cancer Genetics Q4 Revenues Grow 4 Percent
Nov 19, 2012